|
Trans-NIH Structural Birth Defects Working Group (SBDWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDCD, NIDCR, NIDDK, NIEHS, NINDS
|
The Trans-NIH SBDWG brings together extramural program officials from NIH components whose missions include research into structural birth defects, with the ultimate goal of facilitating advances in our understanding of the etiology, mechanisms, epidemiology, prevention, and treatment of structural birth defects.
|
|
Trans-NIH Working Group for Objective Measures in Cancer
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NIBIB, NIDDK
|
An National Institutes of Health (NIH) working group was formed to develop and consolidate wearable, passive and continuous out-of-clinic monitoring strategies for clinical assessment and understanding of disease progression in cancer. The goal of this group and its activities is to examine how these devices and techniques can be used to assess and understand cancer progression from multi-parameter data (context, vitals, and/or chemistry). Currently, several non-HHS agencies (National Institute of Standards and Technology (NIST), Department of Defense (DoD), Department of Energy (DOE), the National Aeronautics and Space Administration (NASA) and HHS agencies (NIH and the Food and Drug Administration) are also involved in these discussions and will integrate their expertise/mission to propagate for medical purposes.
|
|
Transformation of PROWL Survey into Electronic Form.
|
Health Survey
|
FDA
|
NEI, NLM
|
In 2016, the Food and Drug Administration (FDA) posted the final version of the Patient-Reported Outcomes with Lasik (PROWL) survey instrument developed in collaboration with the National Eye Institute (NEI) and the Department of Defense (DoD). The survey is intended to collect data to help better understand the potential risk of severe problems that can result from LASIK. The NEI is collaborating with the National Library of Medicine (NLM) to recreate the form in an electronic format to allow for incorporation in electronic data capture systems.
The collaboration worked to make the raw data more accessible and deposited in the Biomedical Research Informatics Computing System (Jan 2018).
|
|
Transplant Cancer Match Study
|
Research Initiative
|
HRSA
|
NCI
|
A study linking databases of US transplant recipients, donors, and waitlist candidates to multiple US cancer registries to evaluate the spectrum of cancer risk in transplant recipients.
|
|
Traumatic Brain Injury Common Data Elements Standards - Interagency Steering Committee
|
Resource Development
|
CDC
|
NINDS, CIT
|
The Traumatic Brain Injury (TBI) Common Data Elements (CDE) Standards - Interagency Steering Committee provides oversight to a Federal scientific initiative to develop and utilize common data elements for TBI.
|
|
Trial to Assess Chelation Therapy 2 (TACT2)
|
Research Initiative
|
CDC
|
NIDDK, NCCIH, NHLBI, NIEHS
|
TACT2 is a clinical trial to determine whether intravenous (IV) Na2EDTA chelation therapy with oral (by mouth) multivitamins will reduce the risk of major cardiovascular events (such as stroke and heart attack) in patients who have already had a heart attack and who also have type 2 diabetes.
|
|
Tribal Epidemiology Centers Program
|
Research Initiative
|
IHS
|
NIMHD
|
The Tribal Epidemiology Centers Program develops Epidemiology Centers and public health infrastructure for American Indian/Alaska Native communities.
|
|
Tribal Health Research Advisory Council (HRAC)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA
|
NIMHD
|
The National Institutes of Health (NIH) supports the activities of the Tribal Health Research Advisory Council (HRAC), including obtaining input from tribal leaders on health research priorities and needs, and dissemination of information.
|
|
Tularemia Animal Model Qualification Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA
|
NIAID
|
This working group is collaborating on the qualification of a primate model of pneumonic tularemia under the Food and Drug Administration (FDA) Animal Model Qualification/Drug Development Tools Program. Animal model qualification is a regulatory decision and will be published on the FDA website when final. The collaboration includes the exchange of study data, study reports, and agreements on regulatory strategy for model qualification.
|
|
U.S. FDA Medical Imaging Drugs Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
CC
|
The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs.
|